Switch theme
Sign up to access all valuation multiples
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty.
2014
26
LTM Revenue $2.4M
LTM EBITDA n/a
$3.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Longeveron has a last 12-month revenue of $2.4M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Longeveron achieved revenue of $2.4M and an EBITDA of -$15.6M.
Longeveron expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Longeveron valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.7M | $2.4M | XXX | XXX | XXX |
| Gross Profit | $0.5M | $0.2M | XXX | XXX | XXX |
| Gross Margin | 70% | 9% | XXX | XXX | XXX |
| EBITDA | -$20.1M | -$15.6M | XXX | XXX | XXX |
| EBITDA Margin | -2833% | -651% | XXX | XXX | XXX |
| Net Profit | -$18.8M | -$21.4M | XXX | XXX | XXX |
| Net Margin | -2657% | -895% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Longeveron's stock price is $1.
Longeveron has current market cap of $21.6M, and EV of $3.8M.
See Longeveron trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.8M | $21.6M | XXX | XXX | XXX | XXX | $-2.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Longeveron has market cap of $21.6M and EV of $3.8M.
Longeveron's trades at 1.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Longeveron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Longeveron and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.8M | XXX | XXX | XXX |
| EV/Revenue | 1.6x | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | XXX | XXX |
| P/E | -1.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpLongeveron's NTM/LTM revenue growth is 5%
Longeveron's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Longeveron's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Longeveron's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Longeveron and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 237% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -651% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -23% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -646% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 429% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 340% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 769% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Longeveron acquired XXX companies to date.
Last acquisition by Longeveron was XXXXXXXX, XXXXX XXXXX XXXXXX . Longeveron acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Longeveron founded? | Longeveron was founded in 2014. |
| Where is Longeveron headquartered? | Longeveron is headquartered in United States of America. |
| How many employees does Longeveron have? | As of today, Longeveron has 26 employees. |
| Who is the CEO of Longeveron? | Longeveron's CEO is Mr. Mohamed Wael Ahmed Hashad. |
| Is Longeveron publicy listed? | Yes, Longeveron is a public company listed on NAS. |
| What is the stock symbol of Longeveron? | Longeveron trades under LGVN ticker. |
| When did Longeveron go public? | Longeveron went public in 2021. |
| Who are competitors of Longeveron? | Similar companies to Longeveron include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Longeveron? | Longeveron's current market cap is $21.6M |
| What is the current revenue of Longeveron? | Longeveron's last 12-month revenue is $2.4M. |
| What is the current EV/Revenue multiple of Longeveron? | Current revenue multiple of Longeveron is 1.6x. |
| What is the current revenue growth of Longeveron? | Longeveron revenue growth between 2023 and 2024 was 237%. |
| Is Longeveron profitable? | Yes, Longeveron is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
